Open Trials
Ovary
AGO-OVAR 27 / WoO
Window-of-opportunity proof-of-concept, non-randomized, open-label, phase II trial of Olaparib given alone (cohort A) or in combination with Durvalumab (cohort B) prior to primary debulking surgery in histologically proven high-grade epithelial ovarian cancer (EOC)
AGO-OVAR 28
Niraparib vs Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial)
AGO-OVAR 2.44 / GLORIOSA
Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
AGO-OVAR 2.45 / REJOICE-Ovarian 01
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
https://clinicaltrials.gov/study/NCT06161025
AGO-OVAR 2.46 / RAMP 301
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (RAMP 301)
https://clinicaltrials.gov/study/NCT06072781
Endometrium / Vulva / Cervix
AGO-EN 11 / DESTINY Endometrial 02
A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy With or Without Radiotherapy as Adjuvant Treatment for HER2-Expressing (IHC 3+/2+) Endometrial Cancer (DESTINY-Endometrial02/ GOG-3122/ ENGOT-en30/GINECO)
AGO-VULVA 1 / PIERCE
Pembrolizumab in combination with lenvatinib in patients with recurrent, persistent, metastatic or locally advanced vulvar cancer not amenable to curative surgery or radiotherapy (PIERCE)
Surgical and translational issues
AGO-OVAR OP.11 / STREAM I
Evaluation of preoperative clinical and translation selection criteria for cytoreductive surgery in endometrial cancer – A retrospective multicenter trial with an accompanying translational project
TUBA-WISP-II
TUBectomy with delayed oophorectomy as Alternative for risk-reducing salpingo-oophorectomy in high-risk Women to assess the Safety of Prevention: TUBA-WISP II